HIV/AIDS
Conditions
Brief summary
In natural HIV disease, a small fraction (1-2%) of infected individuals develops exceptionally high titres of HIV-1 neutralizing serum activity. Antibodies isolated from these individuals have been shown to be highly active against a broad range of different HIV strains and are therefore called broadly neutralizing antibodies (bNAbs). These antibodies are in fact able to prevent (S)HIV infection in animal models and therefore of great interest for the development of an HIV vaccine. Information of neutralizing antibodies in patients from Africa is still scarce and would be of great value in the development of adapted HIV vaccine strategies in these regions. This study aims to investigate African HIV-infected individuals, who have developed neutralizing antibodies using highly specialized laboratory methodologies.
Interventions
None listed
Sponsors
National Institute for Medical Research - Mbeya Medical Research Centre (NIMR-MMRC)
University Clinic of Cologne, Department of Internal Medicine, Center for Molecular Medicine Cologne (CMMC)
Max von Pettenkofer-Institute of the University of Munich (LMU), Department of Virology
Michael Hoelscher
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntary and informed consent 2. ≥18 years of age 3. Documented HIV infection. 4. Willing to consent to active tracing including home tracing
Exclusion criteria
1. Deficiency, rendering it difficult, if not impossible, to take part in the study or understand the information provided. This includes alcoholism, drug dependency as well as psychiatric illnesses, suicidal tendencies or any other inability. 2. Prisoners 3. If within the discretion of the investigator study participation would possibly add not acceptable risk or burden to patient (e.g. significant health deficiencies, social harm) 4. Unlikely to comply with protocol as judged by the principal investigator or his designate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Broadly HIV-1 neutralizing antibodies (bNAb) | December 31, 2018 | identify HIV-infected patients which exhibit exceptional HIV-1 neutralizing activity (so called elite neutralizer) and to perform in those patients in depth characterization including: * Detailed analysis of anti-HIV antibody response using single B cell analyis * Isolation of broadly neutralizing anti-HIV antibodies * Testing of in vitro neutralizing activity and binding properties of newly identified bNAbs * Analysis of the antiviral activity and in vivo characteristics of broadly neutralizing antibodies using a HIV-1-infected humanized mouse model |
Secondary
| Measure | Time frame |
|---|---|
| To characterize HIV subtypes in elite neutralizer and optionally in non-neutralizer | December 31, 2018 |
| To characterize demographic and HIV status related factors associated with elite neutralizers and non-neutralizers | December 31, 2018 |
| To optionally investigate the proportion of patients with transmitted drug mutations (genotypic drug resistance) | December 31, 2018 |
Countries
Tanzania
Outcome results
None listed